If AI is applied to the research and development of new drugs, from target discovery to the determination of clinical candidate compounds, research and development time and funding will be greatly reduced, and the biopharmaceutical industry landscape may suddenly undergo significant changes. Disruptive technology is so cruel and novel, but it is a "strategic battleground" for Shanghai to lead productivity to achieve new breakthroughs. Recently, Shanghai has released three major action plans for the biopharmaceutical industry, promoting the development of the three cutting-edge tracks of synthetic biology, gene therapy, and medical robotics, finding the right source of power, playing the first game, unleashing new energy, and cultivating "nuclear explosion points". Under the efforts of a group of enterprises, the three cutting-edge tracks are accelerating the formation of new quality productive forces, showcasing the strength of Shanghai's science and technology innovation. "In the past 10 years, we have been specializing in the development of new gene editing tools because we need to break through barriers," said Yao Xuan, co-founder, president, and general manager of Huida Gene in Greater China. Currently, the core of gene editing is still CRISPR-Cas9, the third-generation gene editing technology known as the "Gene Magic Scissor" and awarded the 2020 Nobel Prize in Chemistry. More than 90% of biology laboratories worldwide are using this technology, and its underlying patents are still in the hands of European and American countries. "These emerging editing systems are very cutting-edge, and the process of making products is challenging. There is not much experience or mature path to refer to internationally," said Yao Xuan. At present, Huida Gene has obtained patent authorizations from China and the United States for its various new targeted DNA and RNA gene editing technologies. We not only have RNA editing technology, but also DNA editing technology reserves. This solves the intellectual property bottleneck problem for the landing and commercialization of gene editing technology products in China in the future. Cell gene therapy is undoubtedly one of the innovative methods that promote the rapid development of China's biopharmaceutical industry. However, unlike cell therapy products that have already been approved for marketing in China, the field of gene therapy urgently needs a domestically independently developed approved product to give newcomers some confidence. "Tianze Yuntai has chosen the commercialization path of 'transforming one mature technology into another', committed to transforming completely innovative biotechnology and disruptive ideas into valuable experience in traditional Chinese medicine," said Zhao Xiaoping, CEO and co-founder of Tianze Yuntai. Within two years of its establishment, Tianze Yuntai has achieved clinical approval for two products under research, especially the VGR-R01 product for the indication of crystalline retinitis pigmentosa (BCD), which is unique. It is the world's first gene therapy product developed for crystalline retinitis pigmentosa and has completed phase I and phase II clinical trials so far. As a new type of productive force, synthetic biotechnology must face a mature production system formed through long-term technological evolution at the product level, drawing the "industrial landscape" of the health track. In the commercialization stage, how to move from "mass production" to "market" tests the enterprise's own industrialization ability and insight into the future market size of product selection. Amino acid molecular formula, protein structure diagram... In a conference room of Changjin Biology, graffiti composed of biotechnology elements is dotted on all four walls. Through a glass wall, you can see the bottles in the microbiology laboratory